Vaccination for Children of H&O and Their Parents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to study on compliance, safety and effectivity of vaccination for children with hematologic malignancies or solid tumors and their parents.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

NCT00001566

Ewing's Sarcoma Rhabdomyosarcoma

COMPLETED PHASE2

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564

Ewing's Sarcoma Rhabdomyosarcoma

COMPLETED PHASE2

Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy

NCT07240207

Pediatric Solid Tumors

RECRUITING

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

NCT02933333

Acute Myeloid Leukemia Acute Lymphoid Leukemia Lymphoma +3 more

UNKNOWN PHASE4

Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells

NCT05120518

Pediatric Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Children with hematologic malignancies or solid tumors are all facing with immune deficiency due to the disease, the chemotherapy, the hematopoietic stem cell transplantation or the splenectomy, which greatly increases their chance to get infectious diseases. In this study, we will assess the compliance of children with hematologic malignancies or solid tumors and their parents to accept vaccination after finishing treatments, follow up with untoward effect questionnaires to assess the safety, obtain the serum of children patients to test antibody titers and assess the effectivity, provide clues for the study of vaccination in children with hematologic malignancies or solid tumors and provide a scientific basis for the formulation and reunification of vaccination programs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccination Hematologic Malignancy Solid Tumor, Childhood

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low antibody titers

Antibody titers lower than protection level

Group Type EXPERIMENTAL

Vaccination

Intervention Type BIOLOGICAL

Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:

hepatitis B vaccine measles-rubella combined vaccine

high antibody titers

Antibody titers higher than protection level

Group Type OTHER

No Vaccination

Intervention Type OTHER

Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaccination

Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:

hepatitis B vaccine measles-rubella combined vaccine

Intervention Type BIOLOGICAL

No Vaccination

Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children patients(≤18 years) who accepted chemotherapy, hematopoietic stem cell transplantation or splenectomy since our study started.
2. No history of hepatitis B and measles, do not suffer from other diseases that affect immune function and allergic diseases.

Exclusion Criteria

1. Children patients who did not reach clinical remission after treatment, critically ill or eventually died.
2. Patients who used monoclonal antibodies, especially anti-tumor necrosis factors.
3. Intermittent or low-dose chemotherapy or other immunosuppressive drugs users.

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No